表紙:肺動脈性肺高血圧症の世界市場-2023年~2030年
市場調査レポート
商品コード
1297782

肺動脈性肺高血圧症の世界市場-2023年~2030年

Global Pulmonary Arterial Hypertension Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
肺動脈性肺高血圧症の世界市場-2023年~2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

肺動脈性肺高血圧症の世界市場規模は2022年に70億米ドルで、2023~2030年の市場推計・予測期間中にCAGR 5.3%で成長し、2030年には106億米ドルに達すると推定・予測されています。肺高血圧症は完治させることはできないが、薬物療法によって症状を軽減し、患者の管理を助けることができます。

肺高血圧症は時間とともに悪化することが多いです。治療せずに放置すると、心不全を引き起こし、死に至ることもあります。したがって、できるだけ早く治療を開始する必要があります。肺高血圧症が他の病気によって引き起こされている場合は、まずその基礎疾患に対処すべきです。そうすることで、肺動脈への永続的な損傷を避けることができます。

市場力学

高齢者における罹患率の増加

肺動脈性肺高血圧症市場の成長を促進する要因の1つは、老年人口における疾病率の増加です。例えば、最近の研究では、米国と欧州の統計によると、肺動脈性肺高血圧症は、他の心血管系疾患を併存していることが多い高齢者で発見されることが多くなっています。この研究では、肺動脈性肺高血圧症の診断時の年齢の中央値は60歳で、患者の29%が70歳以上であることが判明しました。

肺動脈性肺高血圧症の高額な治療費

肺動脈性肺高血圧症の治療費が高いことは、肺動脈性肺高血圧症市場を停滞させる市場の阻害要因の一つです。研究によると、PAH患者は過剰な薬物使用のために多額の薬局経費を負担しています。

PAHの併用療法はかなり一般的で、PAH患者の46パーセントが二重療法、9パーセントが三重療法を受けており、支払者の負担を増加させる可能性がある2。二重療法と三重療法に関する重要な臨床試験であるTRITONでは、ベースラインに対する肺血管抵抗(PVR)の有意な減少が認められ、これまでの漸進的な治療法のエスカレーションを上回っている3,4。

COVID-19影響分析

COVID-19に伴う肺動脈性肺高血圧症の主な原因機序は、グループ3のPAHと同様に広範な肺障害(間質および肺胞の炎症による)と肺血管系の変化(血栓性/血栓塞栓性プロセスによって誘発される、第4群のPAHと同様、肺血管系の変化(血栓・血栓塞栓過程、内皮傷害、あるいは少なくとも低酸素性血管収縮による)であるが、場合によっては、人工呼吸で使用される呼気終末陽圧の影響も追加要因として考えられます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 老年患者の疾病率の増加
    • 抑制要因
      • 肺動脈性肺高血圧症の治療費の高騰
    • 機会
      • ジェネリック医薬品市場の急成長
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤クラス別

  • プロスタサイクリンおよびプロスタサイクリン類似体
  • カルシウム拮抗薬
  • ホスホジエステラーゼ5(PDE-5)
  • エンドセリン受容体拮抗薬(ERA)
  • その他

第8章 投与経路別

  • 吸入
  • 注射剤
  • 経口投与

第9章 流通チャネル別

  • 病院薬局
  • 薬局店舗
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Arena Pharmaceuticals
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Actelion Pharmaceuticals, Ltd.(Johnson & Johnson)
  • Merck & Co. Inc
  • Novartis International AG
  • Pfizer Inc
  • United Therapeutics Corporation

第13章 付録

目次
Product Code: PH4078

Market Overview

The Global Pulmonary Arterial Hypertension Market size was worth US$ 7 billion in 2022 and is estimated to reach US$ 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2023-2030. Although pulmonary hypertension cannot be cured, medication may reduce symptoms and assist patients in managing the condition.

Pulmonary hypertension often worsens over time. If left untreated, it can lead to cardiac failure, which can be deadly. Thus, treatment should begin as soon as possible. If pulmonary hypertension is caused by another ailment, the underlying condition should be addressed first. This can occasionally avoid lasting damage to the pulmonary arteries.

Market Dynamics

Increased rate of disease of in Geriatric patients

Increased rate of disease in Geriatric patients is one the driver that increases the market growth of the pulmonary arterial hypertension market. For instance, a recent study found that statistics from the United States and Europe show that pulmonary arterial hypertension is increasingly being detected in older individuals, who commonly have other cardiovascular comorbidities. During the study, it was discovered that the median age at the time of diagnosis of pulmonary arterial hypertension was 60 years, and 29% of the patients were 70 years or older.

High cost of treatment of Pulmonary arterial hypertension

High cost of treatment of Pulmonary arterial hypertension is one of the markets hinder which stops the Pulmonary arterial hypertension market for instance, According to studies, individuals with PAH have large pharmacy expenses due to excessive medication use.1 To complicate matters, PAH is frequently treated using injected medications that might be billed under the medical benefit with minimal visibility to cost.

Combination therapy for PAH is fairly common: 46 percent of PAH patients are on dual therapy regimens, and 9 percent are on triple therapy regimens, potentially raising payor expenses.2 TRITON, a crucial trial on double and triple therapy, exhibited significant reductions in pulmonary vascular resistance (PVR) relative to baseline, outperforming previous progressive therapy escalation.3,4 These people are enjoying longer lives and avoiding the need for lung transplants.

COVID-19 Impact Analysis

Covid possesses the main responsible mechanisms for Pulmonary Arterial Hypertension associated with COVID-19 are considered extensive pulmonary damage (due to interstitial and alveolar inflammation) as in PAH of group 3 and alterations in pulmonary vasculature (induced by thrombotic/thromboembolic processes, endothelial injury, or, at the very least, hypoxic vasoconstriction) as in PAH of group 4, but in some cases, an additional factor could be the consequences of positive end-Ex expiratory pressure used in mechanical ventilation.

Segment Analysis

The market for next-generation contact lenses and visual prostheses is segmented by drug class, route of administration, and distribution channel on a global scale.

The Oral Route Of the Administration Segment will be Dominated By Market Players During the Forecast Period.

The Oral route segment, with a percentage of around 44.3%, is dominated by market players' products during the forecast period as it is the most prevalent form of drug administration. It is the preferred method because to its advantages, such as non-invasiveness, patient compliance, and convenience of medicine administration. Medication solubility, mucosal transparency, and the stability of the digestive system environment are all variables that impact oral medication absorption.

Because inhaled drugs specifically target the receptor, they can be supplied at a lower dose than systemic therapies (oral or injectable), resulting in less mild adverse effects. Regarding clinical efficacy, the three types of aerosol devices (MDI, DPI, and nebulizer) may be comparable. As a result, the market for inhalational administration is likely to be the fastest-growing sector.

Geographical Analysis

North America is the dominating region during the forecast period.

North America is estimated to hold around 39.1% of the total market share throughout the forecast period in terms of revenue share. The sophisticated healthcare system in the region, which offers access to innovative therapies, is responsible for a large portion of this. Increased awareness, a high incidence of diagnosis, and favorable government policies contribute to market development.

In North America, pulmonary hypertension is normally diagnosed and managed by specialized healthcare experts such as pulmonologists, cardiologists, and PH specialists. They collaborate with patients to create personalized treatment programs that may include medicines, lifestyle changes, and, in certain situations, sophisticated treatments, including pulmonary arterial hypertension (PAH)-targeted pharmaceuticals, prostacyclin analogs, or lung transplantation.

Competitive Landscape

The major global players include: Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation

  • Why Purchase the Report?
  • To visualize the Global Pulmonary Arterial Hypertension Market segmentation based on the drug class, Route of administration and Distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous Global Pulmonary Arterial Hypertension Market level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Pulmonary Arterial Hypertension Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by drug class
  • 3.2. Snippet by Route of administration
  • 3.3. Snippet by Distribution channel

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase rate of disease in geriatric patients
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of treatment of pulmonary arterial hypertension
    • 4.1.3. Opportunity
      • 4.1.3.1. Rapid growing generic drug market
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1 Prostacyclin and Prostacyclin Analogs
  • 7.2 Calcium Channel Blockers
  • 7.3 Phosphodiesterase 5 (PDE-5)
  • 7.4 Endothelin Receptor Antagonists (ERA)
  • 7.5 Others

8. By Route of Administration

  • 8.1. Inhalation
  • 8.2. Injectable
  • 8.3. Oral Administration

9. By Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Pharmacy Stores
  • 9.3. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Arena Pharmaceuticals
  • 12.3. Bayer AG
  • 12.4. Bristol-Myers Squibb Company
  • 12.5. Gilead Sciences Inc
  • 12.6. GlaxoSmithKline Plc
  • 12.7. Actelion Pharmaceuticals, Ltd. (Johnson & Johnson)
  • 12.8. Merck & Co. Inc
  • 12.9. Novartis International AG
  • 12.10. Pfizer Inc
  • 12.11. United Therapeutics Corporation

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us